{
  "drugs involved": [
    {
      "type": "DIDEO_00000128",
      "id": "48695d2d-9545-4a31-80d1-201d7d7e2cdb"
    },
    {
      "type": "DIDEO_00000128",
      "id": "05b06c16-a763-4ef4-90d8-899abb34abd8"
    }
  ],
  "clinical consequences": {
    "type": "MPIO_0000003",
    "id": "5476c5b5-b52b-4750-882d-cc47f4fa52f4",
    "display": "Decreased efficacy relative to treatment for chronic myeloid leukemia.",
    "concept set references": [
      {
        "type": "TextQuoteSelector",
        "exact": "chronic myeloid leukemia",
        "body": {
          "type": "SemanticTag",
          "value": "2e1bca79-953c-4ea3-9c40-4c16da2dde31"
        }
      }
    ]
  },
  "seriousness": {
    "type": "MPIO_0000009",
    "id": "d8ea3c5c-bc25-4cca-b9a8-ed742742e741",
    "value": "serious",
    "display": "A decrease in chronic myeloid leukemia treatment efficacy is a serious potential clinical consequence because it can result in death, life-threatening hospitalization, and disability."
  },
  "mechanism of interaction information": {
    "type": "MPIO_0000005",
    "id": "8a8ce6c0-c78e-4d38-bda2-835118f976ea",
    "display": "These TKIs demonstrate pH dependent absorption for oral administration which may result in decreased efficacy when given concomitantly with medications that increase gastric pH."
  },
  "frequency of exposure to the PDDI": {
    "type": "MPIO_0000007",
    "id": "56ebf54f-a148-4f2d-9924-b44f174ea72e",
    "display": "Unknown"
  },
  "frequency of harm for persons who have been exposed to the PDDI": {
    "type": "MPIO_0000006",
    "id": "207ae890-3098-436d-b248-578279c65d9c",
    "display": "Unknown"
  },
  "modifying factors information": {
    "type": "MPIO_0000000",
    "id": "b4566e23-3884-495f-93e1-04a0b5c9a008",
    "expressionLogic": "human readable",
    "members": [
      {
        "display": "The TKI is imatinib or ponatinib",
        "operational classification statement": {
          "type": "MPIO_0000111",
          "display": "No special precautions."
        },
        "evidence about a suspected drug-drug interaction": {
          "type": "MPIO_0000004",
          "display": "Imatinib and ponatinib AUCs are not appreciably decreased by PPI co-administration.",
          "References": [
            {
              "title": "Iclusig",
              "author": [
                {
                  "name": "ARIAD Pharmaceuticals, Inc."
                }
              ],
              "type": "package insert",
              "year": "2016",
              "link": [
                {
                  "url": "https://specialtydrug.magellanprovider.com/media/32235/iclusig.pdf"
                }
              ]
            },
            {
              "title": "Effect of a proton pump inhibitor on the pharmacokinetics of imatinib",
              "author": [
                {
                  "name": "Merrill J Egorin"
                },
                {
                  "name": "Dhvani D Shah"
                },
                {
                  "name": "Susan M Christner"
                },
                {
                  "name": "Mara A Yerk"
                },
                {
                  "name": "Kristin A Komazec"
                },
                {
                  "name": "Leonard R Appleman"
                },
                {
                  "name": "Robert L Redner"
                },
                {
                  "name": "Brian M  Miller"
                },
                {
                  "name": "Jan H Beumer"
                }
              ],
              "type": "article",
              "year": "2009",
              "journal": {
                "name": "British journal of clinical pharmacology",
                "volume": "68",
                "number": "3",
                "pages": "370--374"
              },
              "link": [
                {
                  "url": "https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2009.03466.x"
                }
              ],
              "identifier": [
                {
                  "type": "doi",
                  "id": "10.1111/j.1365-2125.2009.03466.x"
                }
              ]
            }
          ]
        },
        "concept set references": [
          {
            "type": "TextQuoteSelector",
            "attribute": "display",
            "exact": "Imatinib",
            "body": {
              "type": "SemanticTag",
              "value": "bd1da3d0-0543-42b6-9698-62f672d20ea4"
            }
          },
          {
            "type": "TextQuoteSelector",
            "attribute": "display",
            "exact": "ponatinib",
            "body": {
              "type": "SemanticTag",
              "value": "901791fd-5575-49fd-b043-a865743432b6"
            }
          }
        ]
      },
      {
        "display": "The TKI is nilotinib",
        "operational classification statement": {
          "type": "MPIO_0000111",
          "display": "Assess risk and take action if necessary."
        },
        "evidence about a suspected drug-drug interaction": {
          "type": "MPIO_0000004",
          "display": "Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids and H2 antagonists may be considered if TKI is given 2 hours before the antacid/H2 antagonist. However, for nilotinib a retrospective study has shown no difference in cytogenetic response rates for patients taking PPIs.",
          "References": [
            {
              "title": "Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia",
              "author": [
                {
                  "name": "Ophelia QP Yin"
                },
                {
                  "name": "Frank J Giles "
                },
                {
                  "name": "Michele Baccarani"
                },
                {
                  "name": "Philipp Le Coutre"
                },
                {
                  "name": "Ovidiu Chiparus"
                },
                {
                  "name": "Neil Gallagher"
                },
                {
                  "name": "Giuseppe Saglio"
                },
                {
                  "name": "Timothy P Hughes"
                },
                {
                  "name": "Andreas Hochhaus"
                },
                {
                  "name": "Hagop M Kantarjian"
                },
                {
                  "name": "RA Larson"
                }
              ],
              "type": "article",
              "year": "2012",
              "journal": {
                "name": "Cancer chemotherapy and pharmacology",
                "volume": "70",
                "number": "2",
                "pages": "345--350"
              },
              "link": [
                {
                  "url": "https://link.springer.com/article/10.1007/s00280-012-1881-3"
                }
              ],
              "identifier": [
                {
                  "type": "doi",
                  "id": "10.1007/s00280-012-1881-3"
                }
              ]
            }
          ]
        },
        "concept set references": [
          {
            "type": "TextQuoteSelector",
            "attribute": "display",
            "exact": "nilotinib",
            "body": {
              "type": "SemanticTag",
              "value": "d8dc65de-aefc-45a1-a0b5-d576838bcb1b"
            }
          }
        ]
      },
      {
        "display": "The TKI is bosutinib or dasatinib",
        "type": "MPIO_0000111",
        "operational classification statement": {
          "type": "MPIO_0000111",
          "display": "Use only if benefit outweighs risk."
        },
        "evidence about a suspected drug-drug interaction": {
          "type": "MPIO_0000004",
          "display": "Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids and H2 antagonists may be considered if TKI is given 2 hours before the antacid/H2 antagonist.",
          "References": [
            {
              "title": "Sprycel",
              "author": [
                {
                  "name": "Bristol-Myers Squibb Company"
                }
              ],
              "type": "package insert",
              "year": "2015",
              "link": [
                {
                  "url": "https://packageinserts.bms.com/pi/pi_sprycel.pdf"
                }
              ]
            },
            {
              "title": "Bosulif",
              "author": [
                {
                  "name": "Pfizer Labs"
                }
              ],
              "type": "package insert",
              "year": "2015",
              "link": [
                {
                  "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"
                }
              ]
            },
            {
              "title": "Tasigna",
              "author": [
                {
                  "name": "Novartis"
                }
              ],
              "type": "package insert",
              "year": "2015",
              "link": [
                {
                  "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf"
                }
              ]
            }
          ]
        },
        "concept set references": [
          {
            "type": "TextQuoteSelector",
            "attribute": "display",
            "exact": "bosutinib",
            "body": {
              "type": "SemanticTag",
              "value": "3b4fd6a6-15a8-4520-8ec4-ffb62898bc33"
            }
          },
          {
            "type": "TextQuoteSelector",
            "attribute": "display",
            "exact": "dasatinib",
            "body": {
              "type": "SemanticTag",
              "value": "e57501f1-5af2-4479-99c6-dc971e1dec35"
            }
          }
        ]
      }
    ]
  },
  "concept sets": [
    {
      "id": "2e1bca79-953c-4ea3-9c40-4c16da2dde31",
      "display": "chronic myeloid leukemia",
      "type": "SNOMED-CT",
      "system": "https://www.nlm.nih.gov/healthit/snomedct/",
      "members": [
        {
          "type": "IAO_0020000",
          "system": "https://www.nlm.nih.gov/healthit/snomedct/",
          "code": "415287001",
          "display": "Relapsing chronic myeloid leukemia"
        },
        {
          "type": "IAO_0020000",
          "system": "https://www.nlm.nih.gov/healthit/snomedct/",
          "code": "277589003",
          "display": "Atypical chronic myeloid leukemia"
        },
        {
          "type": "IAO_0020000",
          "system": "https://www.nlm.nih.gov/healthit/snomedct/",
          "code": "277587001",
          "display": "Juvenile chronic myeloid leukemia"
        },
        {
          "type": "IAO_0020000",
          "system": "https://www.nlm.nih.gov/healthit/snomedct/",
          "code": "128826001",
          "display": "Atypical chronic myeloid leukemia, BCR/ABL negative"
        }
      ]
    },
    {
      "id": "48695d2d-9545-4a31-80d1-201d7d7e2cdb",
      "display": " tyrosine kinase inhibitors (TKIs)",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE04",
          "display": "sunitinib"
        },
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XC03",
          "display": "trastuzumab"
        },
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XC14",
          "display": "ado-trastuzumab emtansine"
        }
      ]
    },
    {
      "id": "05b06c16-a763-4ef4-90d8-899abb34abd8",
      "display": "proton pump inhibitors",
      "type": "DIDEO_00000128",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "members": [
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "816346",
          "display": " Dexlansoprazole"
        },
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "283742",
          "display": "  Esomeprazole"
        },
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "17128",
          "display": " Lansoprazole"
        },
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "7646",
          "display": " Omeprazole"
        },
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "40790",
          "display": " Pantoprazole"
        },
        {
          "type": "APOLLO_SV_00000461",
          "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
          "code": "114979",
          "display": " Rabeprazole"
        }
      ]
    },
    {
      "id": "bd1da3d0-0543-42b6-9698-62f672d20ea4",
      "display": "Imatinib",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE01",
          "display": "imatinib"
        }
      ]
    },
    {
      "id": "901791fd-5575-49fd-b043-a865743432b6",
      "display": "ponatinib",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE08",
          "display": "ponatinib"
        }
      ]
    },
    {
      "id": "d8dc65de-aefc-45a1-a0b5-d576838bcb1b",
      "display": "nilotinib",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE08",
          "display": "nilotinib"
        }
      ]
    },
    {
      "id": "3b4fd6a6-15a8-4520-8ec4-ffb62898bc33",
      "display": "bosutinib",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE14",
          "display": "bosutinib"
        }
      ]
    },
    {
      "id": "e57501f1-5af2-4479-99c6-dc971e1dec35",
      "display": "dasatinib",
      "type": "DIDEO_00000128",
      "system": "https://www.whocc.no/atc_ddd_index",
      "members": [
        {
          "type": "ATC",
          "system": "https://www.whocc.no/atc_ddd_index",
          "code": "L01XE06",
          "display": "dasatinib"
        }
      ]
    }
  ]
}